ERBB2 and rectal carcinoma: It was discovered in 4.3% of sufferers with increased risk, locally advanced rectal tumor who were subjected to chemoradiation with or without cetuximab in phase II EXPERT-C study [23]. Marshall et al. reported a 5.4% of HER2/neu positivity for rectal carcinomas (Table 2) [24].